FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Leslie Mangold

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Anatomy

Prostate

Physiology

Disease Progression

Co-author Network

Publications

TOP 3
Naoki Terada; David B Yeater; Yu Zeng; PRAKASH KULKARNI; Leslie A Mangold; Steven M Mooney; Alan W Partin; Takumi Shiraishi; Robert H Getzenberg
Cyr61 is regulated by cAMP-dependent protein kinase with serum levels correlating with prostate cancer aggressiveness.
Herbert Lepor; Leslie A Mangold; Daniel W Chan; Carol D Cheli; Juliana Laze; Lori J Sokoll; Samir S Taneja; Robert P Thiel; Alan W Partin
Clinical evaluation of a novel method for the measurement of prostate-specific antigen, AccuPSA(TM) , as a predictor of 5-year biochemical recurrence-free survival after radical prostatectomy: results of a pilot study.
Eddy S Leman; Ahmed Magheli; Grant W Cannon; Leslie A Mangold; Alan W Partin; Robert H Getzenberg
Analysis of a serum test for prostate cancer that detects a second epitope of EPCA-2.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Leslie Mangold (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Naoki Terada; David B Yeater; Yu Zeng; PRAKASH KULKARNI; Leslie A Mangold; Steven M Mooney; Alan W Partin; Takumi Shiraishi; Robert H Getzenberg
Cyr61 is regulated by cAMP-dependent protein kinase with serum levels correlating with prostate cancer aggressiveness.
The Prostate 2012;72(9):966-76.
2012: Herbert Lepor; Leslie A Mangold; Daniel W Chan; Carol D Cheli; Juliana Laze; Lori J Sokoll; Samir S Taneja; Robert P Thiel; Alan W Partin
Clinical evaluation of a novel method for the measurement of prostate-specific antigen, AccuPSA(TM) , as a predictor of 5-year biochemical recurrence-free survival after radical prostatectomy: results of a pilot study.
BJU international 2012;109(12):1770-5.
2009: Eddy S Leman; Ahmed Magheli; Grant W Cannon; Leslie A Mangold; Alan W Partin; Robert H Getzenberg
Analysis of a serum test for prostate cancer that detects a second epitope of EPCA-2.
The Prostate 2009;69(11):1188-94.
2009: Sumit Isharwal; M Craig Miller; Jonathan I Epstein; Leslie A Mangold; Elizabeth Humphreys; Alan W Partin; Robert W Veltri
DNA Ploidy as surrogate for biopsy gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction.
Urology 2009;73(5):1092-7.
2009: David J Hernandez; Misop Han; Elizabeth B Humphreys; Leslie A Mangold; Samir S Taneja; Stacy J Childs; Georg Bartsch; Alan W Partin
Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone.
BJU international 2009;103(5):609-14.
2009: Kazutoshi Fujita; Charles M Ewing; David Y Chan; Leslie A Mangold; Alan W Partin; William B Isaacs; Christian P Pavlovich
Endoglin (CD105) as a urinary and serum marker of prostate cancer.
International journal of cancer. Journal international du cancer 2009;124(3):664-9.
2008: Sumit Isharwal; Michael Craig Miller; Jonathan I Epstein; Leslie A Mangold; Elizabeth Humphreys; Alan W Partin; Robert W Veltri
Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy.
International journal of cancer. Journal international du cancer 2008;123(11):2636-43.
2008: Robert W Veltri; Sumit Isharwal; M Craig Miller; Jonathan I Epstein; Leslie A Mangold; Elizabeth Humphreys; Alan W Partin
Long-term assessment of prostate cancer progression free survival: evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis.
The Prostate 2008;68(16):1806-15.
2008: Kevin H Zhao; David J Hernandez; Misop Han; Elizabeth B Humphreys; Leslie A Mangold; Alan W Partin
External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score.
Urology 2008;72(2):396-400.
2008: Matthew Nielsen; Danil V Makarov; Elizabeth B Humphreys; Leslie A Mangold; Alan W Partin; Patrick C Walsh
Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion--"nadir + 2"?
Urology 2008;72(2):389-93; discussion 394-5.
2008: Stacy Loeb; David J Hernandez; Leslie A Mangold; Elizabeth B Humphreys; Marilyn Agro; Patrick C Walsh; Alan W Partin; Misop Han
Progression after radical prostatectomy for men in their thirties compared to older men.
BJU international 2008;101(12):1503-6.
2008: Michael Müntener; Jonathan I Epstein; David J Hernandez; Mark L Gonzalgo; Leslie A Mangold; Elizabeth B Humphreys; Patrick C Walsh; Alan W Partin; Matthew Nielsen
Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy.
European urology 2008;53(4):767-75; discussion 775-6.
2008: Patrick J Bastian; Ganesh S Palapattu; Srinivasan Yegnasubramanian; Craig G Rogers; Xiaohui Lin; Leslie A Mangold; Bruce J Trock; Mario A Eisenberger; Alan W Partin; William G Nelson
CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer.
The Journal of urology 2008;179(2):529-34; discussion 534-5.
2008: Danil V Makarov; Elizabeth B Humphreys; Leslie A Mangold; Michael A Carducci; Alan W Partin; Mario A Eisenberger; Patrick C Walsh; Bruce J Trock
The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy.
The Journal of urology 2008;179(1):156-61; discussion 161-2.
2007: S Lilly Zheng; Jielin Sun; Yu Cheng; Ge Li; Fang-Chi Hsu; Yi Zhu; Bao-Li Chang; Wennuan Liu; Jin Woo Kim; Aubrey R Turner; Marta Gielzak; Guifang Yan; Sarah D Isaacs; Kathy E Wiley; Jurga Sauvageot; Huann-Sheng Chen; Robin Gurganus; Leslie A Mangold; Bruce J Trock; Henrik Gronberg; David Duggan; John D Carpten; Alan W Partin; Patrick C Walsh; Jianfeng Xu; William B Isaacs
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans.
Journal of the National Cancer Institute 2007;99(20):1525-33.
2007: Patrick J Bastian; Ganesh S Palapattu; Srinivasan Yegnasubramanian; Xiaohui Lin; Craig G Rogers; Leslie A Mangold; Bruce J Trock; Mario A Eisenberger; Alan W Partin; William G Nelson
Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(18 Pt 1):5361-7.
2007: John C Mavropoulos; Alan W Partin; Christopher L Amling; Martha Kennedy Terris; Christopher J Kane; William J Aronson; Joseph C Presti; Leslie A Mangold; Stephen J Freedland
Do racial differences in prostate size explain higher serum prostate-specific antigen concentrations among black men?
Urology 2007;69(6):1138-42.
2007: Danil V Makarov; Bruce J Trock; Elizabeth B Humphreys; Leslie A Mangold; Patrick C Walsh; Jonathan I Epstein; Alan W Partin
Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005.
Urology 2007;69(6):1095-101.
2007: Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario A Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin
Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(13):1765-71.
2007: Eddy S Leman; Grant W Cannon; Bruce J Trock; Lori J Sokoll; Daniel W Chan; Leslie A Mangold; Alan W Partin; Robert H Getzenberg
EPCA-2: a highly specific serum marker for prostate cancer.
Urology 2007;69(4):714-20.
2007: Stephen J Freedland; Alan W Partin; Elizabeth B Humphreys; Leslie A Mangold; Patrick C Walsh
Radical prostatectomy for clinical stage T3a disease.
Cancer 2007;109(7):1273-8.
2006: Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario A Eisenberger; Alan W Partin
Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality.
The Journal of urology 2006;176(4 Pt 1):1404-8.
2006: Patrick J Bastian; Mark L Gonzalgo; William J Aronson; Martha Kennedy Terris; Christopher J Kane; Christopher L Amling; Joseph C Presti; Leslie A Mangold; Elizabeth B Humphreys; Jonathan I Epstein; Alan W Partin; Stephen J Freedland
Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
Cancer 2006;107(6):1265-72.
2006: Danil V Makarov; Elizabeth B Humphreys; Leslie A Mangold; Patrick C Walsh; Alan W Partin; Jonathan I Epstein; Stephen J Freedland
Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
The Journal of urology 2006;176(2):554-8.
2006: Matthew Nielsen; Misop Han; Leslie A Mangold; Elizabeth B Humphreys; Patrick C Walsh; Alan W Partin; Stephen J Freedland
Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center.
The Journal of urology 2006;176(2):515-9.
2006: Mark L Gonzalgo; Patrick J Bastian; Leslie A Mangold; Bruce J Trock; Jonathan I Epstein; Patrick C Walsh; Alan W Partin
Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate.
Urology 2006;67(1):115-9.
2005: Stephen J Freedland; Kelly A Grubb; Sindy K Yiu; Matthew Nielsen; Leslie A Mangold; William B Isaacs; Jonathan I Epstein; Alan W Partin
Obesity and capsular incision at the time of open retropubic radical prostatectomy.
The Journal of urology 2005;174(5):1798-801; discussion 1801.
2005: Stephen J Freedland; Leslie A Mangold; Patrick C Walsh; Alan W Partin
The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy.
The Journal of urology 2005;174(4 Pt 1):1276-81; discussion 1281; author reply 1281.
2005: Stephen J Freedland; Lori J Sokoll; Elizabeth A Platz; Leslie A Mangold; Debra J Bruzek; Phaedre Mohr; Sindy K Yiu; Alan W Partin
Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy.
The Journal of urology 2005;174(4 Pt 1):1266-70.
2005: Stephen J Freedland; Kelly A Grubb; Sindy K Yiu; Elizabeth B Humphreys; Matthew Nielsen; Leslie A Mangold; William B Isaacs; Alan W Partin
Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center.
The Journal of urology 2005;174(3):919-22.
2005: Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario A Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.
JAMA : the journal of the American Medical Association 2005;294(4):433-9.
2005: Patrick J Bastian; Ganesh S Palapattu; Xiaohui Lin; Srinivasan Yegnasubramanian; Leslie A Mangold; Bruce J Trock; Mario A Eisenberger; Alan W Partin; William G Nelson
Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(11):4037-43.
2005: Stephen J Freedland; William B Isaacs; Leslie A Mangold; Sindy K Yiu; Kelly A Grubb; Alan W Partin; Jonathan I Epstein; Patrick C Walsh; Elizabeth A Platz
Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(8):2883-8.
2005: Stephen J Freedland; Lori J Sokoll; Leslie A Mangold; Debra J Bruzek; Phaedre Mohr; Sindy K Yiu; Jonathan I Epstein; Alan W Partin
Serum leptin and pathological findings at the time of radical prostatectomy.
The Journal of urology 2005;173(3):773-6.
2004: Masood A Khan; Lori J Sokoll; Daniel W Chan; Leslie A Mangold; Phaedre Mohr; Stephen D Mikolajczyk; Harry J Linton; Cindy L Evans; Harry G Rittenhouse; Alan W Partin
Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.
Urology 2004;64(6):1160-4.
2004: Masood A Khan; Leslie A Mangold; Jonathan I Epstein; John K Boitnott; Patrick C Walsh; Alan W Partin
Impact of surgical delay on long-term cancer control for clinically localized prostate cancer.
The Journal of urology 2004;172(5 Pt 1):1835-9.
2004: Patrick J Bastian; Leslie A Mangold; Jonathan I Epstein; Alan W Partin
Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis.
Cancer 2004;101(9):2001-5.
2004: Dennis A Faith; William B Isaacs; James D Morgan; Helen Fedor; Jessica L Hicks; Leslie A Mangold; Patrick C Walsh; Alan W Partin; Elizabeth A Platz; Jun Luo; Angelo M DeMarzo
Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays.
The Prostate 2004;61(3):215-27.
2004: Matthew B Gretzer; Daniel W Chan; C L van Rootselaar; Jason Rosenzweig; S Dalrymple; Leslie A Mangold; Alan W Partin; Robert W Veltri
Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOF.
The Prostate 2004;60(4):325-31.
2004: Robert W Veltri; Masood A Khan; M Craig Miller; Jonathan I Epstein; Leslie A Mangold; Patrick C Walsh; Alan W Partin
Ability to predict metastasis based on pathology findings and alterations in nuclear structure of normal-appearing and cancer peripheral zone epithelium in the prostate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(10):3465-73.
2004: Stephen J Freedland; Leslie A Mangold; Jonathan I Epstein; Alan W Partin
Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease.
Urology 2004;63(5):887-91.
2004: Jinong Li; Nicole White; Zhen Zhang; Jason Rosenzweig; Leslie A Mangold; Alan W Partin; Daniel W Chan
Detection of prostate cancer using serum proteomics pattern in a histologically confirmed population.
The Journal of urology 2004;171(5):1782-7.
2003: Masood A Khan; Patrick C Walsh; M Craig Miller; Wesley D Bales; Jonathan I Epstein; Leslie A Mangold; Alan W Partin; Robert W Veltri
Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy.
Cancer 2003;98(12):2583-91.
2003: Jae Park; Lori J Sokoll; Debra J Bruzek; Leslie A Mangold; Robin Gurganus; Masood A Khan; Alan W Partin; Daniel W Chan; Robert W Veltri
Comparison of total prostate-specific antigen and derivative levels in a screening population of black, white, and Korean-American men.
Clinical prostate cancer 2003;2(3):173-6.
2003: Masood A Khan; Alan W Partin; Leslie A Mangold; Jonathan I Epstein; Patrick C Walsh
Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer.
Urology 2003;62(5):866-71.
2003: John J Hlavaty; Alan W Partin; Matthew J Shue; Leslie A Mangold; Jennifer Derby; Teofilo Javier; Shane Kelley; Adam Stieg; Joseph V Briggman; G Michael Hass; Ying-Jye Wu
Identification and preliminary clinical evaluation of a 50.8-kDa serum marker for prostate cancer.
Urology 2003;61(6):1261-5.
2003: Lori J Sokoll; Daniel W Chan; Stephen D Mikolajczyk; Harry G Rittenhouse; Cindy L Evans; Harry J Linton; Leslie A Mangold; Phaedre Mohr; Georg Bartsch; Helmut Klocker; Wolfgang Horninger; Alan W Partin
Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis.
Urology 2003;61(2):274-6.
2002: Lori J Sokoll; Leslie A Mangold; Alan W Partin; Jonathan I Epstein; Debra J Bruzek; Willard Dunn; Phaedre Mohr; Gail Wallerson; Daniel W Chan
Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men.
Urology 2002;60(4 Suppl 1):18-23.
2002: Robert W Veltri; M Craig Miller; Leslie A Mangold; Gerard J O'Dowd; Jonathan I Epstein; Alan W Partin
Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
The Journal of urology 2002;168(1):100-4.
2001: Alan W Partin; Leslie A Mangold; D M Lamm; Patrick C Walsh; Jonathan I Epstein; Jay D Pearson
Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium.
Urology 2001;58(6):843-8.
2000: Steven R Potter; Leslie A Mangold; Matthew J Shue; D C Taylor; Kristin Lecksell; Jonathan I Epstein; Patrick C Walsh; Alan W Partin
Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative pelvic lymph nodes at radical prostatectomy.
Cancer 2000;89(12):2577-86.
1999: Steven R Potter; M Craig Miller; Leslie A Mangold; K A Jones; Jonathan I Epstein; Robert W Veltri; Alan W Partin
Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy.
Urology 1999;54(5):791-5.